Form 4 for IONS IONIS PHARMACEUTICALS INC
Accepted 2026-07-06 18:49:29 ET · period of report 2026-07-01 · accession 0000874015-26-000229 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-07-06 18:49 | 2026-07-01 | IONS | KLEIN JOSEPH III | Dir | M - OptEx | $39.94 | +11.5K | 22.5K | +105% | +$460.0K |
| DMT | 2026-07-06 18:49 | 2026-07-01 | IONS | KLEIN JOSEPH III | Dir | S - Sale+OE | $79.04 | -11.5K | 11.0K | -51% | -$910.4K |
| DT | 2026-07-06 18:49 | 2026-07-01 | IONS | KLEIN JOSEPH III | Dir | M - OptEx | $0.00 | -11.5K | 0 | -100% | $0 |
| DMT | 2026-07-06 18:49 | 2026-07-01 | IONS | KLEIN JOSEPH III | Dir | A - Grant | $0.00 | +7,670 | 16.3K | +89% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-01 | M | A | 11,518 | $39.94 | 22,532 | D | — | — | |
| 2 | Common | Common Stock | 2026-07-01 | S | D | 99 | $79.45 | 22,433 | D | — | — | (F1) Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. |
| 3 | Common | Common Stock | 2026-07-01 | S | D | 11,419 | $79.04 | 11,014 | D | — | — | (F1) Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.39 to $79.38 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. |
| 4 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-07-01 | M | D | 11,518 | $0.00 | 0 | D | $39.94 · 2026-07-01 to 2035-06-30 | 11,518 Common Stock | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-07-01 | A | A | 5,369 | $0.00 | 5,369 | D | $79.19 · 2027-07-01 to 2036-06-30 | 5,369 Common Stock | (F4) Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. (F5) Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026. (F5) Grant on July 1, 2026 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2026. |
| 6 | Derivative | Restricted Stock Unit | 2026-07-01 | A | A | 2,301 | $0.00 | 16,277 | D | $0.00 · — to — | 2,301 Common Stock | (F6) Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. (F4) Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2026 totals no more than $400,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718. (F7) Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026. (F7) Grant of Restricted Stock Unit award on July 1, 2026 to the reporting person under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier; however, the reporting person has elected to defer delivery of such shares until the earlier to occur of the 30th day following the reporting person's Separation from Service from the Company or the date of a Change in Control of the Company, both as defined in Treasury Regulation Section 1.409A. These Restricted Stock Units are vested as to 0 shares on July 1, 2026. |